MedPageToday -- The novel anti-arrhythmic vernakalant wins out over amiodarone (Cordarone) for rapid restoration of sinus rhythm in new-onset atrial fibrillation, researchers affirmed in a randomized trial.
MedPageToday -- The novel anti-arrhythmic vernakalant wins out over amiodarone (Cordarone) for rapid restoration of sinus rhythm in new-onset atrial fibrillation, researchers affirmed in a randomized trial.
